波生坦联合西地那非治疗先天性心脏病合并肺动脉高压患儿的临床疗效及安全性评价

发布时间：2018-05-05 02:19

  本文选题：波生坦 + 西地那非　； 参考：《中国医院药学杂志》2017年04期

【摘要】：目的:探讨波生坦联合西地那非治疗先天性心脏病合并肺动脉高压患儿的临床疗效及不良反应发生情况。方法:选择2015年1月到2016年1月某院收治的90例先天性心脏病合并肺动脉高压患儿,随机分为对照组和试验组,各45例。对照组患儿给予西地那非治疗,试验组患儿给予波生坦联合西地那非治疗,两组患儿均治疗3个月。评价并比较两组患儿的临床疗效。检测并比较两组患儿治疗前后WHO肺动脉高压功能分级。采用右心导管检测测量并比较两组患儿治疗前后平均肺动脉压(m PAP)和肺血管阻力(PVR)。观察并比较两组患儿治疗期间不良反应的发生情况。结果:治疗后,试验组患儿的总有效率为95.56%,明显高于对照组患儿的73.33%,差异具有统计学意义(χ~2=8.46,P=0.003 6)。治疗前,两组WHO肺动脉高压功能分级比较差异无统计学意义(P0.05);治疗后,两组WHO肺动脉高压功能Ⅱ级患儿均明显多于治疗前,WHO肺动脉高压功能Ⅲ级、Ⅳ级患儿均明显少于治疗前,差异均具有统计学意义(P0.05),同时试验组WHO肺动脉高压功能Ⅱ级患儿均明显多于对照组,WHO肺动脉高压功能Ⅲ级、Ⅳ级患儿均明显少于对照组,差异均具有统计学意义(P0.05)。治疗前,两组患儿的m PAP、PVR比较,差异均无统计学意义(P0.05);治疗后,两组患儿的m PAP、PVR均明显小于治疗前,并且试验组患儿的m PAP、PVR均明显小于对照组,差异均具有统计学意义(P0.05)。治疗期间,两组患儿的不良反应发生率比较,差异无统计学意义(χ~2=1.01,P=0.908)。结论:波生坦联合西地那非治疗先天性心脏病合并肺动脉高压患儿临床疗效显著,且安全性较好,值得在临床上推广应用。
[Abstract]:Objective: to investigate the clinical efficacy and adverse reactions of Bosentan combined with sildenafil in the treatment of children with congenital heart disease complicated with pulmonary hypertension. Methods: from January 2015 to January 2016, 90 children with congenital heart disease complicated with pulmonary hypertension were randomly divided into control group and experimental group with 45 cases each. Patients in the control group were treated with sildenafil, and those in the experimental group were treated with Bosentan combined with sildenafil for 3 months. To evaluate and compare the clinical efficacy of the two groups. The functional grades of WHO pulmonary hypertension before and after treatment were detected and compared between the two groups. Right cardiac catheterization was used to measure and compare the mean pulmonary artery pressure (MPP) and pulmonary vascular resistance (PVR) before and after treatment. To observe and compare the occurrence of adverse reactions during treatment in two groups. Results: after treatment, the total effective rate of the test group was 95.566.It was significantly higher than that of the control group (73.33%), and the difference was statistically significant (蠂 ~ 2 + 8.46%, P < 0.0036). Before treatment, there was no significant difference in functional grading of WHO pulmonary hypertension between the two groups (P 0.05). After treatment, the number of WHO pulmonary hypertension grade 鈪，

本文编号：1845744